Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02140554 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease
A Phase 1 study, sponsored by Genetix Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT02140554 is a Phase 1 study that has completed, run by Genetix Biotherapeutics. The registered enrollment target is 54 participants.
The verdict
NCT02140554, a Phase 1 study, has completed, sponsored by Genetix Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
This is a non-randomized, open label, multi-site, single dose, Phase 1/2 study in approximately 50 adults and adolescents with severe SCD. The study will evaluate hematopoietic stem cell and progenitor stem cell (collectively referred to as hematopoietic stem and progenitor cells or HSPCs) transplantation using lovo-cel.
Interventions
- GENETIC lovo-cel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2015-02-02 |
| Est. Completion | 2024-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02140554
The ClinicalTrials.gov registry entry for NCT02140554 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genetix Biotherapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lovo-cel is the first listed.
NCT02140554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02140554 about?
NCT02140554 is a clinical study titled "A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease". This is a non-randomized, open label, multi-site, single dose, Phase 1/2 study in approximately 50 adults and adolescents with severe SCD. The study will evaluate hematopoietic stem cell and progenitor stem cell (collectively referred to as hematopoietic stem and progenitor cells or HSPCs) transplan...
What is the current status of trial NCT02140554?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2015-02-02. Estimated completion is 2024-01-30.
What interventions are being tested in trial NCT02140554?
The interventions under investigation include: lovo-cel (GENETIC).
Who is sponsoring clinical trial NCT02140554?
This trial is sponsored by Genetix Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.